Effects of cyclooxygenase inhibitor treatment on the renal toxicity of cisplatin in rats
| Autor: | Brenda M. Johnson, José A. Ramos-Vara, Bruce A. Craig, Lindsey M. Fourez, Steven B. Hooser, Shawna N. Greene, Cheryl Anderson, Deborah W. Knapp, Jane C. Stewart |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Cancer Research Pilot Projects Pharmacology Toxicology Piroxicam Rats Sprague-Dawley chemistry.chemical_compound Antineoplastic Combined Chemotherapy Protocols medicine Animals Pharmacology (medical) Cyclooxygenase Inhibitors Cisplatin Creatinine Kidney biology Behavior Animal Dose-Response Relationship Drug Rats Dose–response relationship medicine.anatomical_structure Oncology chemistry Toxicity biology.protein COX-2 inhibitor Kidney Diseases Cyclooxygenase medicine.drug |
| Zdroj: | Cancer chemotherapy and pharmacology. 65(3) |
| ISSN: | 1432-0843 |
| Popis: | The purpose of this study was to determine the effects of a nonselective cyclooxygenase (cox) inhibitor and of a selective cox-2 inhibitor on the renal toxicity of cisplatin. Cisplatin with or without a cox-1 inhibitor (SC560), a cox-2 inhibitor (SC236), or a nonselective cox inhibitor (piroxicam) was administered to Sprague–Dawley rats. Renal toxicity was assessed by serum creatinine concentration (SCR), urine specific gravity (USG), and histopathologic lesion score (HLS). Acutely, the SCR was significantly higher in rats receiving cisplatin/SC560 (1.62 ± 0.34 mg/dl) or cisplatin/piroxicam (2.0 ± 0.41 mg/dl) than in rats receiving cisplatin alone (1.09 ± 0.40 mg/dl). The apparent increase in SCR in the rats receiving cisplatin/SC236 (1.58 ± 0.31) was not significantly different from that of rats receiving cisplatin alone (1.09 ± 0.40 mg/dl). No significant differences in USG or HLSs were noted between rats receiving cisplatin alone and cisplatin combined with any cox inhibitor. In a chronic study, no differences in renal toxicity were found between rats treated with cisplatin alone and cisplatin/SC236 or cisplatin/piroxicam. The acute rise in SCR following cisplatin treatment can be worsened by the addition of cox inhibitors, especially those that inhibit cox-1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink